Table 2.
Clinical and Pathological Features of Patients with Cutaneous Malignant Melanoma by Sex
| Variable | Total % (N = 1,279) | Men % (N = 678) | Women % (N = 601) | p | Variable | Total % (N = 1,279) | Men % (N = 678) | Women % (N = 601) | p |
|---|---|---|---|---|---|---|---|---|---|
| Tumor site | <0.001 | Breslow thickness | 0.098 | ||||||
| Trunk | 46.4 (593) | 59.3 (402) | 31.8 (191) | ≤0.75 | 54.2 (693) | 51.0 (346) | 57.7 (347) | ||
| Lower limbs | 20.3 (260) | 9.9 (67) | 32.1 (193) | 0.76–1.50 | 18.4 (236) | 18.9 (128) | 18.0 (108) | ||
| Head | 10.4 (133) | 10.8 (73) | 10.0 (60) | 1.51–3.99 | 14.0 (179) | 16.1 (109) | 11.6 (70) | ||
| Upper limbs | 15.2 (195) | 13.4 (91) | 17.3 (104) | ≥4 | 8.3 (106) | 8.8 (60) | 7.7 (46) | ||
| Hands/feet | 4.4 (56) | 2.9 (20) | 6.0 (36) | Missing | 5.1 (65) | 5.2 (35) | 5.0 (30) | ||
| Missing | 3.3 (42) | 3.7 (25) | 2.8 (17) | Mitotic number | 0.747 | ||||
| Ulceration | 0.454 | 0–2 | 62.4 (798) | 61.8 (419) | 63.1 (379) | ||||
| Absent | 78.4 (1,003) | 77.1 (523) | 79.9 (480) | ≥2 | 19.7 (252) | 20.5 (139) | 18.8 (113) | ||
| Present | 15.8 (202) | 17.0 (115) | 14.5 (87) | Missing | 17.9 (229) | 17.7 (120) | 18.1 (109) | ||
| Missing | 5.8 (74) | 5.9 (40) | 5.6 (34) | TILs | 0.004 | ||||
| Histological subtype | 0.053a | Absent | 14.8 (189) | 12.1 (82) | 17.8 (107) | ||||
| Superficial spreading m. | 72.4 (926) | 70.9 (481) | 74.0 (445) | Present | 72.5 (927) | 76.3 (517) | 68.2 (410) | ||
| Nodular m. | 12.4 (159) | 14.5 (98) | 10.2 (61) | Missing | 12.7 (163) | 11.6 (79) | 14.0 (84) | ||
| Lentigo maligna m. | 2.2 (28) | 2.2 (15) | 2.2 (13) | Tumor regression | 0.043 | ||||
| Acral-lentiginous m. | 1.9 (25) | 1.2 (8) | 2.8 (17) | Absent | 41.4 (530) | 38.2 (259) | 45.1 (271) | ||
| Desmoplastic m. | 0.3 (4) | 0.3 (2) | 0.3 (2) | Present | 24.8 (317) | 26.0 (176) | 23.5 (141) | ||
| M. in blue nevus | 0.1 (1) | 0.0 (0) | 0.2 (1) | Missing | 33.8 (432) | 35.8 (243) | 31.4 (189) | ||
| Spitzoid m. | 2.2 (28) | 1.6 (11) | 2.8 (17) | TNM stage | 0.058 | ||||
| Malignant melanoma, not otherwise specified | 5.8 (74) | 6.2 (42) | 5.3 (32) | I–II (early stages) | 84.4 (1,079) | 82.8 (561) | 86.2 (518) | ||
| Missing | 2.7 (34) | 3.1 (21) | 2.2 (13) | III–IV (advanced stages) | 11.2 (143) | 13.1 (89) | 9.0 (54) | ||
| Growth phase | 0.153 | ||||||||
| Missing | 22.9 (293) | 55.3 (165) | 54.2 (128) |
a
Fisher's test was applied, otherwise the chi-squared test was used.
TILs, tumor-infiltrating lymphocytes.